U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H12N2O8.2Na.2H
Molecular Weight 336.2063
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EDETATE DISODIUM ANHYDROUS

SMILES

[H+].[H+].[Na+].[Na+].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O

InChI

InChIKey=ZGTMUACCHSMWAC-UHFFFAOYSA-L
InChI=1S/C10H16N2O8.2Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;/q;2*+1/p-2

HIDE SMILES / InChI

Description

Edetic acid (EDTA) is a chelating agent. The U.S. Food and Drug Administration (FDA) approved edetic acid chelation therapy as a treatment for lead and heavy metal poisoning. Edetic acid in form of disodium salt was withdrawn from the market due to death resulting from hypocalcemia during chelation.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
18.3 null [pKd]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Calcium disodium versenate
Curative
Calcium Disodium Versenate
Curative
Unknown
Curative
Unknown
Diagnostic
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
51 μg/mL
1 g single, intramuscular
EDETATE CALCIUM DISODIUM serum
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
60 min
unknown, unknown
EDETATE CALCIUM DISODIUM plasma
Homo sapiens

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
hypercalcemia: adults: 50 mg/kg/day (up to 3 g/day) administered by slow IV infusion. Frequency and duration of administration are quite variable, and should be determined based on the patient's serum calcium. Five consecutive daily doses may be administered, followed by 2 days without medication, repeating these courses as necessary to a total of 15 doses.
Route of Administration: Other
In Vitro Use Guide
Unknown